RTI Biologics Inc.  

(Public, NASDAQ:RTIX)   Watch this stock  
Find more results for RTIX
3.74
+0.18 (5.06%)
Real-time:   12:09PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.71 - 3.81
52 week 2.82 - 4.79
Open 3.75
Vol / Avg. 140,370.00/147,182.00
Mkt cap 208.82M
P/E 24.70
Div/yield     -
EPS 0.15
Shares 55.83M
Beta 1.50
Inst. own 79%
Jul 31, 2012
Q2 2012 RTI Biologics, Inc. Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '12) 2011
Net profit margin 2.92% 4.95%
Operating margin 3.72% 6.95%
EBITD margin - 11.69%
Return on average assets 2.28% 3.68%
Return on average equity 3.01% 5.01%
Employees 706 -
Carbon Disclosure Rating - -

Address

11621 Research Circle
ALACHUA, FL 32615
United States - Map
+1-386-4188888 (Phone)
+1-386-4180342 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

RTI Biologics, Inc. process human musculoskeletal and other tissue. It also processes bone, cartilage, tendon, ligament, fascia lata, pericardium, sclera and dermal tissue, and bovine animal tissue in producing allograft and xenograft implants utilizing BIOCLEANSE and TUTOPLAST sterilization processes, for distribution to hospitals and surgeons. It process at two facilities in Alachua, Florida and one facility in Neunkirchen, Germany and distributes its products and services in all 50 states and in over 30 countries worldwide. The Company processs human and bovine animal tissue and distribute the tissue through various distribution channels. Its lines of business are consists primarily of five product categories: sports medicine, spine, dental, surgical specialties, Bone graft substitutes (BGS) and general orthopedic.

Officers and directors

Dean H. Bergy Independent Chairman of the Board
Age: 52
Bio & Compensation - Reuters
Brian K. Hutchison President, Chief Executive Officer, Director
Age: 52
Bio & Compensation - Reuters
Robert P. Jordheim Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation - Reuters
Thomas F. Rose Chief Operating Officer, Executive Vice President, Corporate Secretary
Age: 61
Bio & Compensation - Reuters
Caroline A. Hartill Executive Vice President, Chief Scientific Officer
Age: 55
Bio & Compensation - Reuters
Roger W. Rose Executive Vice President, Chief Commercial Officer and President - RTI Donor Services
Age: 52
Bio & Compensation - Reuters
Julianne M. Bowler Independent Director
Age: 48
Bio & Compensation - Reuters
Philip R. Chapman Independent Director
Age: 50
Bio & Compensation - Reuters
Roy D. Crowninshield Ph.D. Independent Director
Age: 63
Bio & Compensation - Reuters
Peter F. Gearen M.D. Independent Director
Age: 63
Bio & Compensation - Reuters